INTRODUCTION
Among the myriad of challenges encountered in delivering care to children with cancer in low and middle income countries is the provision of medicines-both antineoplastic drugs and those used for supportive care. [1] A key issue is the identification of the priority medicines for supply in the public sector, and here the role played by the World Health Organization (WHO) has been critical. The first WHO model list of essential medicines (EML) was produced in 1977 and is reviewed every two years. In 1985 WHO established a list of 14 essential medicines for cancer, making no distinction between agents for adults and children. [2] This list was updated a decade later in 1994 by the Expert Committee on the Use of Essential Drugs; [3] adding a further 10 chemotherapeutic agents deemed essential. The list was re-visited 5 years later when 17 drugs were identified as priority one drugs for cancer and thus essential; four specifically for leukemias. [4] A separate Model List of essential medicines for children (EMLc) was created in 2007. The 2011 EMLc update took a disease-based approach to cancers resulting in the inclusion of medicines for the treatment of acute lymphoblastic leukemia, Burkitt lymphoma, and Wilms tumor. Independently, the Essential Medicines Working Group of the International Society of Pediatric Oncology (SIOP) has proposed a list of antineoplastic drugs and those used for supportive care, with a focus on low and middle income countries, that provides a notable expansion of the EMLc. [5] The 2013 EMLc included only 14 antineoplastic drugs, four of which are corticosteroids. Missing from this list and included in the SIOP EML are bleomycin, carboplatin, cisplatin, dacarbazine, etoposide, hydroxyurea, ifosfamide, and vinblastine; all included in current standard treatment protocols and a number of these are in the adult WHO EML. Within the past year, the Union for International Cancer Control (UICC) has engaged with WHO to promote further additions to the Model List with input from the SIOP Working Group. The Model List is made available to the governments of all countries as a guide to developing the national essential medicines lists (NEMLs) that underpin the acquisition of essential medicines for the public sector. From a survey undertaken by WHO, more than 90% of low and middle income countries use their NEMLs for the procurement of medications. [6] Member States are encouraged to provide their NEMLs and lists of medicines reimbursed in health insurance programs (national reimbursable medicines lists-NRMLs) to WHO for inclusion in its publicly accessible websites.
Challenges to providing access to medicines for patients with cancer in low-resource settings include government underfunding of medicines and institutional weaknesses in the pharmaceutical sector for procuring and supplying medicines that contribute to poor inventory control and potentially suboptimal utilization of these products. [7] Possible solutions to improve access to medicines include the establishment of universal insurance coverage to pool resources, provide financial protection, address equity concerns and empower consumers, [7] and the use of generic off-patent and biosimilar medications. Access may be enhanced also by participation in clinical trials, especially when these are funded by the pharmaceutical industry. [7] Abbreviations: AGHE, annual government health expenditure; EML, model list of essential medicines; GAVI, global alliance for vaccines and immunizations; GHO, global health observatory; GNI, gross national income; HIC, high income country; LIC, low income country; LMIC, lower middle income country; NCD, The high price of some drugs for the treatment of cancer is a complex challenge, [8] and all-too-often is a major obstacle to the provision of appropriate care for children with cancer in low and middle income countries. [9] Yet treatment in these circumstances is demonstrably very cost-effective. [10] Indeed the Institute of Medicine in the USA has identified the treatment of highly curable cancers in young people as one of the three main strategies to address the global cancer crisis. [11] The governing tenet expressed by the Ponte di Legno Working Group a decade ago remains in force; that it is the right of all children in the world to have full access to the essential treatment of cancer. [12] On this background, a study was undertaken to examine the extent to which antineoplastic drugs in the SIOP EML that are deemed to be essential in the care of children with cancer in low and middle income countries are included in NEMLs and NRMLs. Relationships between the numbers of medicines included and a number of financial and workforce characteristics were examined.
METHODS
The study began following the methods of Kirby et al. [13] who explored the access, in 81 low and middle income countries, to the 15 antimicrobial drugs proposed in the SIOP EML to be essential in the supportive care of children with cancer. With a few exceptions (Benin, Burkina Faso, Democratic Republic of the Congo, India, Togo, and Tuvalu), EMLs did not have separate lists of antineoplastic drugs for adults and children. Data for the antineoplastic medicines of interest were extracted from the sources identified and the adult and child lists combined, reasoning that all could be made available for children.
The data were extracted independently by the authors, and discrepancies resolved by consensus and re-checking the relevant source documents. The documents used were in a wide variety of formats. Some presented the information according to categories of clinical utilization, similar to the WHO Model List; others listed drugs by brand name only, by supplier (manufacturer or distributor), in an alphabetical list, or in multiple Excel worksheets making data extraction challenging. Translations were obtained for EMLs or NRMLs using the Cyrillic alphabet (Belarus, Russia, Tajikistan, Ukraine, and Uzbekistan) and for Mongolia.
Data on the corticosteroids listed in the SIOP EML were excluded, reducing the primary list to 18 cytotoxic agents. The ancillary medicines in the SIOP EML were retained. The vitamin A analogs tretinoin (all-trans retinoic acid) and isotretinoin (13-cisretinoic acid) were listed more often as dermatological preparations, but were included in the data extraction no matter how identified.
The proportions of countries listing each antineoplastic drug and all of these drugs together were calculated. Information on gross national income (GNI) per capita, annual government health expenditure (AGHE) per capita, and number of physicians per 1,000 people were obtained for each country. GNI per capita was based on the Atlas method rather than purchasing power parity and obtained from the World Bank (http://data.worldbank.org/news/ 2015-country-classifications). The Atlas method for GNI per capita ranking was chosen over the purchasing power parity approach as it dampens the variability in estimates associated with fluctuations in exchange rates. An upper limit of US $25,000 for GNI per capita was set to minimize the "ceiling effect"; wealthier countries are likely to have all of the selected antineoplastic drugs listed. Categorization of low, lower-middle-income, upper-middle-income and high-income countries was accomplished by the criteria of the World Bank: low-income countries (LICs)-US $1,045 GNI per capita or less; lower-middle-income (LMIC)-US $1,046 to $4,125; uppermiddle-income (UMIC)-US $4,126 to $12,745; and high-income countries (HICs)-US $12,746 or greater. AGHE per capita and numbers of physicians per 1,000 people were obtained from the WHO's Global Health Observatory (GHO) for the same period (http:// apps.who.int/gho/data/view.main.1920ALL?lang=en and http://www. who.int/gho/health_workforce/physicians_density/en, respectively).
It was hypothesized that GNI per capita, AGHE per capita, and the number of physicians per million people would each relate directly to the listing of antineoplastic drugs.
RESULTS
Information was available from 135 countries that met the inclusion criteria. By the World Bank categories there were 26 LICs, 42 LMICs, 44 UMICs, and 20 HICs in the study sample (Table I) . Cook Islands, Nauru, and Niue could not be categorized. There were no EMLs or NRMLs for 20 additional countries meeting the inclusion criteria (Table I) . Using the most recent data from any source, the median year of EML or NMRL was 2010 (minimum 2004, maximum 2014); there were undated lists for three countries (Cote d'Ivoire, Gabon, and Myanmar). There were differences between the two WHO website sources with 15 countries having national EMLs or NRMLs in Source A (alphabetical listing) but not in Source B (information portal) and 18 with entries in Source B but not in Source A. Where country lists were available in both sources, it was not consistent which source provided the more recent document. An additional five lists were obtained from WHO country offices and four were located by Internet searches. Numerous Pacific Island countries either listed no cytotoxic agents (Marshall Islands, Niue, Palau) or only one or two medicines (Cook Islands, Nauru, Tonga, Tuvalu, and Vanuatu), always including methotrexate.
The proportions of countries listing each of the 18 essential antineoplastic drugs ranged from 27% for thioguanine to 95% for methotrexate (Table II) . The median number of drugs included was 13 (minimum 0, maximum 18). None of the 15 countries listing all 18 essential medicines was a LIC. For the ancillary list of eight medicines, the median was one (minimum zero, maximum eight) across all 135 countries.
The proportions of countries including the 18 essential medicines in national lists according to World Bank income groupings are shown in Table III . The median number of medicines listed was seven (minimum 0, maximum 17) in LICs and 14 in LMICs, UMICs, and HICs. There was considerable variability in the numbers of medicines listed within income groupings, although a consistent trend was observed toward more medicines being included as GNI per capita increased, with correlations statistically significant for the list of 18 essential medicines and the eight ancillary medicines (Table IV) . Only 19% of LICs included 13 or more of the 18 essential medicines in their national lists compared to 70% of HICs.
There was considerable variability in the numbers of cancer medicines listed within all WHO regional groupings ( Table V) . The median number of medicines was lowest in the Africa region, home to 20 of the 26 LICs included in this study. The lower estimate for the Western Pacific region overall was due largely to the inclusion of a number of small Pacific Island countries that provide limited cancer services themselves, relying on referral services to neighboring HICs.
There was little or no correlation between AGHE per capita and the numbers of essential medicines listed, but a significant correlation existed with the numbers of ancillary medicines (Table IV) . Strong correlations were found between inclusion of medicines and the number of physicians per million population; r ¼ 0.25 and r ¼ 0.50 for essential and ancillary medicines respectively (Table IV) .
DISCUSSION
Within the study sample of 135 countries there was wide variability in the listing of individual medicines in national EMLs and NRMLs, and in the proportion of the drugs recommended by the SIOP Working Group [5] included in these documents.
The virtual absence of cytotoxic agents in the lists supplied by a number of Pacific Island countries with small populations reflects the common practice of referring patients with cancer elsewhere for treatment e.g., to Australia and New Zealand.
The GNI per capita correlates inversely with the under five mortality rate [14, 15] generally held to be a good measure of the health of a population, [16] and the AGHE per capita correlates directly with the average 5-year survival rate for children with cancer in low and middle income countries. [17] There was overall a statistically significant correlation between the listing of antineoplastic drugs and GNI per capita, as hypothesized, consistent with the findings of Bazargani et al. on a selection of essential antineoplastic drugs in NEMLs from 76 countries. [18] However, the correlation with AGHE per capita was approximately zero. This is exemplified by Myanmar that, in an undated list, included all but Pediatr Blood Cancer DOI 10.1002/pbc one of the SIOP essential drugs yet had an AGHE per capita of US $4.7, calling into question the reality of access to drugs in that country, at least in the public sector. As a corollary, Slovenia had the highest AGHE per capita (US $1,423.
3) yet only two of the nominated 18 essential cytotoxic drugs were listed in the Seznam Nujno Potrebnih Zdravil Za Uporabo V Human Medicini, 2012 (List of Essential Medicines for Human Use, 2012). However, an earlier 2010 list for Slovenia (found in Source A), identified more essential medicines for cancer. A further list of "Indispensable Medicinal Products" is referenced on the Agency of the Republic of Slovenia for Medicinal Products and Medical Devices website (http://www.jazmp.si/en/human_medicines/indispensable_medicinal_ products/), illustrating the challenge of finding the most complete and relevant list of medicines at the country level for inclusion in the study. The strongest correlation was between the density of physicians in a population and the number of SIOP essential drugs; [5] a plausible cause-and-effect relationship. The number of physicians per capita is a decidedly important variable as it is associated with the child, infant and maternal mortality rates, after controlling for the Gross National Product per capita, the Gini coefficient of income inequality, and the female literacy rate. [15] In the 47 Member States of the WHO African Region, the average density of physicians was about fivefold lower than the global average. [19] Bazargani et al. [18] observed an association between the number and diversity of antineoplastic agents and the cancer burden in the countries that they studied, but noted also "Surprisingly, categories of antineoplastic agents frequently used as routine chemotherapy agents were not found among essential medicines in a notable fraction of all studied countries. This category includes medicines which have extensive indications in various types of malignancy." The results of our study, that focuses on the listing of specific agents rather than classes of medicines, accord with this observation. The 18 cytotoxic drugs, proposed by SIOP to be essential for the treatment of cancer in children, have been accessible for decades. With the exception of asparaginase, these drugs are also inexpensive by comparison with some agents used in the treatment of carcinomas in adults, prompting a call for more studies of cost-effectiveness. [20] Clearly there is room for substantial improvement in the information provided in WHO's public websites. Efforts should be made to maintain an up-to-date list of national EMLs and NRMLs using a standard reporting format, preferably with information also available in English. At least for cytotoxic agents, there seems little value in maintaining separate NEMLs for adults and children as the same medicines are used in each group.
The prevention and treatment of cancers is an important part of the UN Global Action Plan for the management of noncommunicable diseases. Access to essential medicines was recognized as a critical element in ensuring equity of access to effective treatments in a 2014 World Health Assembly resolution (http://apps.who.int/medicinedocs/en/d/Js21453ar/), with national EMLs and health insurance lists as important tools to prioritize medicines and promote access.
The present report provides the most comprehensive review to date of the status of essential medicines for cancers in children with a dominant focus on low and middle income countries that bear the largest burden of malignant disease in this age group. [21] Although comprehensive, the report has important limitations. EMLs or NRMLs were not available for some countries, some available documents were undated, and there may have been more recent versions of the documents not included in the sources used. However, the WHO websites may be regarded as the "report card" for Member States, and are an important resource for research and comparative analyses. The focus of this report is the listing of medicines on NEMLs and NRMLs. Although not a measure of availability and access directly, it is an important step supporting procurement in the public sector and thereby promoting access, availability, and affordability that are major barriers to the delivery of chemotherapy for children with cancer in low and middle income countries. Lists were matched for specific agents and in some cases there may have been other chemotherapeutic agents that were reasonable substitutes for the nominated medicines. However, the SIOP EML represents a considered approach to identifying effective and affordable cytotoxics that can be administered safely in resource-constrained settings. The study provides no information on the affordability of these medicines for cancer. The low AGHE per capita in many of the countries included in the study suggests that public sector procurement is likely to be problematic, thus denying many children access to curative and life-prolonging therapies. In addition to assessing the availability and affordability of cancer care at the country level, it is important to monitor the outcomes of treatment, particularly in light of the chronic shortages of trained health care professionals, especially in Africa. The SIOP Working Group has an important role to play in working with WHO and other partners to identify the priority essential medicines for cancers in children, while supporting national efforts in low and middle income countries to develop effective and affordable cancer care services.
More than a decade ago, Hans Hogerzeil concluded that "The selection of essential medicines based on sound scientific review and public health grounds, the development of evidence-based national clinical guidelines and a national medicines policy are the cornerstones of any essential medicines program." [22] It is hoped that the results of the present study will contribute to an improvement in the access by children with cancer to effective antineoplastic medicines, especially in low and middle income countries, and so to enhancing their prospects for cure. 
